Inhibition of hepatic sulfatase-2 In Vivo: A novel strategy to correct diabetic dyslipidemia

Hepatology

Volumn 55, Issue 6, 2012, Pages 1746-1753

  Hassing, H Carlijne ^a   Mooij, Hans ^a   Guo, Shuling ^b   Monia, Brett P ^b   Chen, Keyang ^c   Kulik, Wim ^a   Dallinga Thie, Geesje M ^a   Nieuwdorp, Max ^a   Stroes, Erik S G ^a   Williams, Kevin Jon ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ISIS PHARMACEUTICALS   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORN OIL; DISACCHARIDE; HEPARAN; HEPARAN SULFATE GLUCOSAMINE 6 O ENDOSULFATASE 2; MESSENGER RNA; PHOSPHATE BUFFERED SALINE; SULFATASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DYSLIPIDEMIA; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE TARGETING; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; LIPID DIET; LIVER CELL; LIVER LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HEPATOCYTES; HUMANS; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; OLIGONUCLEOTIDES, ANTISENSE; SULFATASES; TRIGLYCERIDES;

EID: 84861545181     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25580     Document Type: Article

References (41)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172.
3. Moreton JR. Atherosclerosis and alimentary hyperlipemia. Science 1947; 106: 190-191.
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749.
5. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006; 35: 491-498.
6. Williams KJ, Tabas I. Lipoprotein retention-and clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005; 25: 1536-1540.
7. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316.
8. Williams KJ. Molecular processes that handle-and mishandle-dietary lipids. J Clin Invest 2008; 118: 3247-3259.
9. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-2152.
10. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
11. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-1226.
12. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-160.
13. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
14. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, III, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
15. Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol 2010; 21: 218-228.
16. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest 2007; 117: 94-98.
17. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 1992; 267: 13284-13292.
18. Ji ZS, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995; 36: 583-592.
19. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007; 117: 153-164.
20. Fuki IV, Kuhn KM, Lomazov IR, Rothman VL, Tuszynski GP, Iozzo RV, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997; 100: 1611-1622.
21. Fuki IV, Meyer ME, Williams KJ. Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts. Biochem J 2000; 351: 607-612.
22. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 2009; 119: 3236-3245.
23. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-393.
24. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446: 1030-1037.
25. Chen K, Liu ML, Schaffer L, Li M, Boden G, Wu X, Williams KJ. Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. HEPATOLOGY 2010; 52: 1957-1967.
26. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002; 277: 49175-49185.
27. Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets 2010; 14: 935-949.
28. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293.
29. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997; 272: 11994-12000.
30. Oguma T, Tomatsu S, Montano AM, Okazaki O. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem 2007; 368: 79-86.
31. Lawrence R, Lu H, Rosenberg RD, Esko JD, Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods 2008; 5: 291-292.
32. Quistorff B, Dich J, Grunnet N. Preparation of isolated rat liver hepatocytes. In: Pollard JW, Walker JM, eds. Methods in Molecular Biology: Animal Cell Culture (vol. 5). Totowa, NJ: Humana; 1989: 151-160.
33. Williams KJ, Liu ML, Zhu Y, Xu X, Davidson WR, McCue P, Sharma K. Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes 2005; 54: 1116-1122.
34. Lee SH, Park S, Kang SM, Jang Y, Chung N, Choi D. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2012; 17: 65-71.
35. Castro Cabezas M, Erkelens DW, Kock LA, De Bruin TW. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 1994; 24: 669-678.
36. van Wijk JP, Buirma R, van Tol A, Halkes CJ, De Jaegere PP, Plokker HW, et al. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2005; 178: 147-155.
37. Twickler TB, Dallinga-Thie GM, de Valk HW, Schreuder PC, Jansen H, Castro Cabezas M, Erkelens DW. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2422-2427.
38. Wilmink HW, Twickler MB, Banga JD, Dallinga-Thie GM, Eeltink H, Erkelens DW, et al. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. Cardiovasc Res 2001; 50: 577-582.
39. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002; 51: 1028-1034.
40. Zhang H, Lowenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684-4692.
41. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-1735.